From Specialty Pharmacy News - In late March the FDA approved the much-anticipated oral multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate). Known as BG-12 as it was undergoing clinical trials, the Biogen Idec therapy has been hailed as a potential blockbuster by industry insiders and analysts. However, it may be a bit of time before plans will make formulary decisions on the drug beyond a basic prior authorization as they wait to see what the real-world data look like. Read more
From Specialty Pharmacy News - In many care situations, home infusion may be the best treatment option for both health plans and their members. And when companies offer this care, it’s important that provider teams include a dietitian who is involved in the management of each patient. A recent Walgreens Infusion Services study involving 2,500 people receiving enteral nutrition (EN) — meaning they are receiving nutrition through a feeding tube — and 270 receiving parenteral nutrition… Read more
From Drug Benefit News - As CMS continues to place emphasis on medication adherence in its star quality ratings for Medicare Part D plan sponsors, plans that employ an integrated strategy with their PBMs are at an advantage when it comes to boosting adherence, suggested executives from Florida Blue and Blues plan-owned PBM Prime Therapeutics LLC during a recent AIS webinar. Read more
Check out all of the benefits, sample issues & more!